DEF: Absci Aims to Redefine Biologics Creation with AI, Eyes Clinical-Stage Transformation

Absci leverages generative AI to accelerate biologics creation, advancing internal pipeline and strategic partnerships towards becoming a clinical-stage biotech company.

Summary

• Absci is using generative AI to create better biologics faster, targeting challenging therapeutic areas.
• In 2024, Absci made significant advancements in its internal pipeline, strategic partnerships, and AI platform.
• The company unveiled ABS-201, a potential treatment for androgenic alopecia, designed with a novel mechanism and showing promising preclinical results.
• ABS-101, an anti-TL1A antibody program, is set to enter Phase 1 trials with interim clinical data expected later this year.
• Absci secured new partnerships with Memorial Sloan Kettering Cancer Center, Owkin, Twist, and Invetx.
• The company's AI platform demonstrated its ability to design novel antibodies targeting HIV's 'Caldera' epitope in collaboration with Caltech and the Gates Foundation.
• Absci's platform relies on proprietary data, leading AI models, an interdisciplinary team, and compute at scale.
• In 2025, Absci anticipates sustained momentum across its pipeline and new partnership opportunities.
• The Annual Meeting of Stockholders will be held virtually on June 11, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with advancements in the pipeline, strategic partnerships, and AI platform. The company's transition to a clinical-stage biotech is a significant milestone, contributing to the positive sentiment.

Positives

• Absci's generative AI platform is capable of designing novel therapeutics for challenging disease targets.
• ABS-201 shows promise as a potential treatment for androgenic alopecia with a novel mechanism and encouraging preclinical results.
• ABS-101 is advancing to Phase 1 trials, indicating progress in the company's clinical pipeline.
• Strategic partnerships with leading institutions and companies validate Absci's platform and its potential across diverse therapeutic areas.
• The company's platform has demonstrated the ability to unlock previously undruggable biology, as shown by the HIV antibody design collaboration.
• Absci is becoming a clinical-stage biotech company in 2025, marking a significant milestone.

Future Outlook

Absci anticipates sustained momentum across its pipeline and new partnership opportunities, including collaborations with major pharmaceutical companies, with a focus on developing impactful therapies.

Management Comments

• At Absci, we're using generative AI at scale to create better biologics faster, addressing some of the most challenging therapeutic targets in biology today.
• Critically, our technology proved capable of unlocking biology that traditional discovery methods have struggled to address, highlighting our unique potential to develop differentiated therapies.
• In 2025, Absci becomes a clinical-stage biotech companya transformative milestone demonstrating the power of generative AI in drug creation.

Industry Context

Absci's focus on AI-driven drug discovery aligns with the growing trend of leveraging technology to accelerate and improve the drug development process. The company's partnerships with major pharmaceutical companies and research institutions indicate a recognition of its potential within the industry.

Comparison to Industry Standards

• Absci's approach to drug discovery using generative AI can be compared to companies like Recursion Pharmaceuticals and Exscientia, which also utilize AI to accelerate drug development.
• The partnerships with Memorial Sloan Kettering Cancer Center, Owkin, Twist, and Invetx are similar to collaborations seen between biotech companies and research institutions to advance drug discovery and development.
• The advancement of ABS-101 to Phase 1 trials is a key milestone, comparable to other biotech companies progressing their lead assets through clinical development.

Related Party Transactions

• Certain holders of more than five percent (5%) of our capital stock and their affiliated entities purchased shares of our common stock in our underwritten common stock offering, which closed on March 1, 2024 (the '2024 Offering'), for payment in excess of $120,000.

Stakeholder Impact

• Shareholders: The company's progress and future outlook may positively impact shareholder value.
• Employees: The company's growth and success can create opportunities for employees.
• Patients: The development of new therapies can benefit patients with unmet medical needs.
• Partners: Strategic partnerships can lead to mutual benefits and advancements in drug discovery and development.

Next Steps

• Advance ABS-101 to Phase 1 clinical trials and report interim clinical data.
• Accelerate the development of ABS-201.
• Pursue new partnership opportunities, including collaborations with major pharmaceutical companies.
• Continue to develop and refine the company's AI platform.

Key Dates

Keywords

generative AI, biologics, antibody design, drug creation, clinical trials, partnerships, ABS-201, ABS-101, AI platform, biotech